Scientists unlock secrets of flu Vaccine's age gap
NCT ID NCT06501963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at why the live attenuated influenza vaccine (LAIV), given as a nasal spray, is less effective in adults than in children. Researchers measured antibody levels in 51 healthy adults after vaccination to understand the immune response. The goal is to use these insights to design better flu vaccines for everyone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Live attenuated influenza vaccine (FluMist nasal spray)
- What this could lead to
- If successful, this research could help design more effective flu vaccines for adults.
- What could go wrong
- This is a small, completed study focused on understanding immune responses, not testing a new treatment. Results may not directly lead to better vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts